The Toronto Stock Exchange is dominated by energy and financial stocks. But over the past few months, one of the best-performing sectors on the TSX has been healthcare, led by Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX), an acquisitive drug company whose stock has jumped 52% this year. The stock is expensive, but is it worth considering for your diversified portfolio? Valeant has made more than 30 acquisitions in the past five years, most recently purchasing Salix Pharmaceuticals for a price of $173 per share in cash, amounting to approximately US$11 billion. Valeant outbid Dublin-based generic drug specialist Endo International for Salix. A few days prior to the purchase, Valeant issued more than seven million common shares for gross proceeds of about $1.45 billion. Prior to Salix, Valeant made an unsuccessful bid to acquire Allergan, Inc., which ultimately teamed up with Actavis plc.